Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study
Brandenburg, Vincent Matthias × Schlieper, Georg Heussen, Nicole Holzmann, Stefan Busch, Birgit Evenepoel, Pieter Vanholder, Raymond Meijers, Björn Meert, Natalie Fassbender, Walter J Floege, Jürgen Jahnen-Dechent, Willi Ketteler, Markus #
Cardiovascular morbidity and mortality are massively increased in patients with chronic kidney disease (CKD). Sevelamer hydrochloride has been shown to attenuate cardiovascular calcifications in CKD and end-stage renal disease (ESRD) patients. We assessed how sevelamer hydrochloride influences the evolution of serum fetuin-A and other serological factors predicting cardiovascular outcome and survival in haemodialysis patients.